Conflict of interest between professional medical societies and industry: a cross-sectional study of Italian medical societies’ websites

Abstract

ObjectiveTo describe how Italian medical societies interact with pharmaceutical and medical device industries through an analysis of the information available on their websites.DesignCross sectional study.SettingItaly.Participants154 medical societies registered with the Italian Federation of Medical-Scientific Societies.Main outcome measuresIndicators of industry sponsorship (presence of industry sponsorship in the programme of the last medical societies’ annual conference; presence of manufacturers’ logos on the homepage; presence of industry sponsorship of satellite symposia during the last annual conference).Results131 Italian medical societies were considered. Of these, 4.6% had an ethical code covering relationships with industry on their websites, while 45.6% had a statute that mentioned the issue of conflict of interest and 6.1% published the annual financial report. With regard to industry sponsorship, 64.9% received private sponsorship for their last conference, 29.0% had manufacturers’ logos on their webpage, while 35.9% had industry-sponsored satellite symposia at their last conference. The presence of an ethical code on the societies’ websites was associated with both an increased risk of industry sponsorship of the last conference (relative risk (RR) 1.22, 95% CIs 1.01 to 1.48 after adjustment) and of conferences and/or satellite symposia (RR 1.22, 95% CIs 1.02 to 1.48 after adjustment) but not with the presence of manufacturers’ logos on the websites (RR 1.79, 95% CIs 0.66 to 4.82 after adjustment). No association was observed with the other indicators of governance and transparency.ConclusionsThis survey shows that industry sponsorship of Italian medical societies’ conferences is common, while the presence of a structured regulatory system is not. Disclosure of the amount of industry funding to medical societies is scarce. The level of transparency therefore needs to be improved and the whole relationship between medical societies and industry should be further disciplined in order to avoid any potential for conflict of interest.

Identifying competing interest disclosure in systematic reviews of surgical interventions and devices: a cross-sectional survey

“…Competing interest in biomedical research has often been associated with a positive conclusion with suppression of negative results [19,20,[37][38][39]. However, we did not nd the association between positive conclusion and competing interest disclosure in our study.…”

Prescribing pattern of antihypertensive drugs in two European cohorts: a population-based database study

“…Another important factor is the marketing policies used by the pharmaceutical industry, primarily to target GPs. Indeed, up to several years ago pharmaceutical companies were one of the main sources of information for GPs in both countries [26,27].…”

Closed Financial Loops: When They Happen in Government, They're Called Corruption; in Medicine, They're Just a Footnote

“…Of 154 Italian medical societies, 65 percent received private sponsorship for their last conference, 29 percent had manufacturers' logos on their webpage, and 36 percent had industry-sponsored satellite symposia at their last conference. 26 A large study showed that financial relationships between organizations that produce medical guidelines and individuals who sit on guidelines committees are common and that poor disclosure of conflict is linked to more positive statements about patented biomedical products. 27 Conflicts of interest surrounding guidelines do not produce concerns just about treatment but also about disease classification and diagnostic tools.…”